Pharmaceutical

Taiho exercises option for Arcus Biosciences’ quemliclustat in Asia

Taiho has exercised an option for an exclusive licence for Arcus Biosciences’ quemliclustat (AB680) in Japan and Asian territories.

Jul 10, 2024 - 04:00
Taiho exercises option for Arcus Biosciences’ quemliclustat in Asia
Taiho has exercised an option for an exclusive licence for Arcus Biosciences’ quemliclustat (AB680) in Japan and Asian territories.
Read the original article

Tags:

Previous Article

SciRhom secures $70m for autoimmune diseases treatments

Next Article

Ligand Pharmaceuticals to acquire APEIRON Biologics for $100m

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Intercept’s liver disease drug Ocaliva faces FDA approval delay

Intercept’s liver disease drug Ocaliva faces FDA approv...

Oct 20, 2024

Celltrion’s SteQeyma receives EC approval for chronic inflammatory diseases

Celltrion’s SteQeyma receives EC approval for chronic i...

Aug 27, 2024

Parkinson’s disease cases to reach 3.15 million in 7MM by 2033

Parkinson’s disease cases to reach 3.15 million in 7MM ...

Nov 21, 2024